Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer - Seite 2
About Relacorilant
Relacorilant is a selective cortisol modulator that binds to the glucocorticoid receptor (GR), but does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety
of serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and
other patents.
About Corcept’s Oncology Programs
Cortisol activity allows solid tumors that express the GR to resist treatment. In some cancers, cortisol inhibits cellular apoptosis — the tumor-killing effect many treatments are meant to
stimulate. In other cancers, cortisol activity promotes tumor growth. Cortisol also suppresses the body’s immune response, weakening the body’s ability to fight certain cancers. Modulating
cortisol’s activity may reduce these adverse effects and help anti-cancer treatments achieve their intended effect.
Corcept is conducting clinical trials of its proprietary compound, relacorilant, in combination with three different anti-cancer treatments in patients with ovarian, adrenal and prostate cancers.
About Corcept Therapeutics
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients across a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary
selective cortisol modulators. Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease (NASH).
In February 2012, the company introduced Korlym, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Corcept is
headquartered in Menlo Park, California. For more information, visit Corcept.com.
Lesen Sie auch
Forward-Looking Statements
Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties
that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties include, but are not limited to, our ability to operate our
business; risks related to the study and development of Korlym as well as relacorilant, miricorilant, dazucorilant and our other product candidates, including their clinical attributes, regulatory
approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. These and other risks are set forth in our SEC filings, which are available
at our website and the SEC’s website.